Syneos Health

One of the largest fully integrated biopharmaceutical solutions companies globally, combining CRO and CCO capabilities under one roof

Syneos Health is a fully integrated biopharmaceutical solutions company offering both clinical development and commercial services to life sciences clients. Formed in 2017 through the merger of INC Research and inVentiv Health, the company rebranded to Syneos Health and grew into one of the largest contract research and commercialization organizations in the world. In 2023, the company was taken private by a consortium of private equity firms including Elliott Investment Management, Patient Square Capital, and Veritas Capital. On the commercial and marketing side, Syneos Health operates Syneos Health Communications, a network of healthcare marketing and communications agencies serving pharmaceutical and biotech brands. This agency network provides services including medical affairs communications, healthcare professional marketing, patient engagement, and brand strategy — making Syneos Health a significant player in healthcare marketing and life sciences advertising. Syneos Health competes with other large contract research organizations (CROs) and contract commercial organizations (CCOs) such as IQVIA, PRA Health Sciences (now part of ICON), and Covance (Labcorp Drug Development). Its integrated model — combining clinical trial management with commercial launch capabilities — is a key differentiator, allowing biopharma clients to work with a single partner from drug development through market launch.